Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 635

1.

Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study.

Gæde P, Oellgaard J, Kruuse C, Rossing P, Parving HH, Pedersen O.

Diabetologia. 2019 Jun 1. doi: 10.1007/s00125-019-4920-3. [Epub ahead of print]

PMID:
31154479
2.

Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.

Winther SA, Øllgaard JC, Tofte N, Tarnow L, Wang Z, Ahluwalia TS, Jorsal A, Theilade S, Parving HH, Hansen TW, Hazen SL, Pedersen O, Rossing P.

Diabetes Care. 2019 May 23. pii: dc190048. doi: 10.2337/dc19-0048. [Epub ahead of print]

PMID:
31123156
3.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
4.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
5.

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.

PMID:
30578152
6.

A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study.

Gæde J, Oellgaard J, Ibsen R, Gæde P, Nørtoft E, Parving HH, Kjellberg J, Pedersen O.

Diabetologia. 2019 Jan;62(1):147-155. doi: 10.1007/s00125-018-4739-3. Epub 2018 Oct 6.

7.

Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.

Oellgaard J, Gæde P, Persson F, Rossing P, Parving HH, Pedersen O.

J Diabetes Complications. 2018 Dec;32(12):1133-1140. doi: 10.1016/j.jdiacomp.2018.09.012. Epub 2018 Sep 24.

PMID:
30282584
8.

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials.

Idzerda NMA, Pena MJ, Parving HH, de Zeeuw D, Heerspink HJL.

Nephrol Dial Transplant. 2018 Sep 1. doi: 10.1093/ndt/gfy159. [Epub ahead of print]

PMID:
30184238
9.

Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients.

Rotbain Curovic V, Hansen TW, Eickhoff MK, von Scholten BJ, Reinhard H, Jacobsen PK, Persson F, Parving HH, Rossing P.

Acta Diabetol. 2018 Nov;55(11):1143-1150. doi: 10.1007/s00592-018-1205-0. Epub 2018 Aug 14.

PMID:
30105469
10.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Dec;20(12):2899-2904. doi: 10.1111/dom.13465. Epub 2018 Aug 5.

11.

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.

Oellgaard J, Gæde P, Rossing P, Rørth R, Køber L, Parving HH, Pedersen O.

Diabetologia. 2018 Aug;61(8):1724-1733. doi: 10.1007/s00125-018-4642-y. Epub 2018 May 30.

12.

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study.

Frimodt-Møller M, von Scholten BJ, Reinhard H, Jacobsen PK, Hansen TW, Persson FI, Parving HH, Rossing P.

PLoS One. 2018 Apr 26;13(4):e0196634. doi: 10.1371/journal.pone.0196634. eCollection 2018.

13.

Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.

Rasmussen DGK, Hansen TW, von Scholten BJ, Nielsen SH, Reinhard H, Parving HH, Tepel M, Karsdal MA, Jacobsen PK, Genovese F, Rossing P.

Diabetes Care. 2018 Jul;41(7):1493-1500. doi: 10.2337/dc17-2392. Epub 2018 Apr 11.

PMID:
29643059
14.

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.

Currie GE, von Scholten BJ, Mary S, Flores Guerrero JL, Lindhardt M, Reinhard H, Jacobsen PK, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.

Cardiovasc Diabetol. 2018 Apr 6;17(1):50. doi: 10.1186/s12933-018-0697-9.

15.

Baseline characteristics and enrichment results from the SONAR trial.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Yi T, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Aug;20(8):1829-1835. doi: 10.1111/dom.13315. Epub 2018 May 1.

16.

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.

Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL.

Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1.

17.

Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.

Agesen RM, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Jensen T, Parving HH, Thorsteinsson B, Tarnow L, Pedersen-Bjergaard U.

Diabetes Technol Ther. 2018 Mar;20(3):247-256. doi: 10.1089/dia.2017.0372. Epub 2018 Mar 12.

PMID:
29565719
18.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2018 Jun;20(6):1369-1376. doi: 10.1111/dom.13245. Epub 2018 Mar 9.

19.

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.

Weldegiorgis M, de Zeeuw D, Li L, Parving HH, Hou FF, Remuzzi G, Greene T, Heerspink HJL.

Am J Kidney Dis. 2018 Jan;71(1):91-101. doi: 10.1053/j.ajkd.2017.08.010. Epub 2017 Nov 16.

PMID:
29153995
20.

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort.

Ferreira I, Hovind P, Schalkwijk CG, Parving HH, Stehouwer CDA, Rossing P.

Diabetologia. 2018 Jan;61(1):231-241. doi: 10.1007/s00125-017-4470-5. Epub 2017 Nov 3.

21.

Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.

Seferovic JP, Pfeffer MA, Claggett B, Desai AS, de Zeeuw D, Haffner SM, McMurray JJV, Parving HH, Solomon SD, Chaturvedi N.

Diabetologia. 2018 Mar;61(3):581-588. doi: 10.1007/s00125-017-4485-y. Epub 2017 Nov 3.

PMID:
29098323
22.

Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.

Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Jorsal A, Parving HH, Tarnow L, Theilade S, Rossing P, Schalkwijk CG, Stehouwer CDA.

Cardiovasc Diabetol. 2017 Oct 25;16(1):139. doi: 10.1186/s12933-017-0620-9.

23.

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.

Webb DJ, Coll B, Heerspink HJL, Andress D, Pritchett Y, Brennan JJ, Houser M, Correa-Rotter R, Kohan D, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Busch R, Pergola P, Parving HH, de Zeeuw D.

Drugs R D. 2017 Sep;17(3):441-448. doi: 10.1007/s40268-017-0201-0.

24.

Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.

Galsgaard J, Persson F, Hansen TW, Jorsal A, Tarnow L, Parving HH, Rossing P.

Kidney Int. 2017 Nov;92(5):1242-1248. doi: 10.1016/j.kint.2017.04.018. Epub 2017 Jul 14.

PMID:
28712855
25.

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.

Zobel EH, von Scholten BJ, Reinhard H, Persson F, Teerlink T, Hansen TW, Parving HH, Jacobsen PK, Rossing P.

Cardiovasc Diabetol. 2017 Jul 11;16(1):88. doi: 10.1186/s12933-017-0569-8.

26.

Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.

Zobel EH, von Scholten BJ, Reinhard H, Persson F, Hansen TW, Parving HH, Jacobsen PK, Rossing P.

Diabetologia. 2017 Oct;60(10):1883-1891. doi: 10.1007/s00125-017-4344-x. Epub 2017 Jul 5.

PMID:
28681124
27.

Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate.

Christensen RH, von Scholten BJ, Hansen CS, Heywood SE, Rosenmeier JB, Andersen UB, Hovind P, Reinhard H, Parving HH, Pedersen BK, Jørgensen ME, Jacobsen PK, Rossing P.

Eur J Prev Cardiol. 2017 Sep;24(14):1517-1524. doi: 10.1177/2047487317717820. Epub 2017 Jun 26.

PMID:
28650207
28.

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA.

Am J Kidney Dis. 2017 Oct;70(4):522-531. doi: 10.1053/j.ajkd.2017.04.018. Epub 2017 Jun 7.

PMID:
28599901
29.

Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study.

Hanssen NMJ, Scheijen JLJM, Jorsal A, Parving HH, Tarnow L, Rossing P, Stehouwer CDA, Schalkwijk CG.

Diabetes. 2017 Aug;66(8):2278-2283. doi: 10.2337/db16-1578. Epub 2017 Jun 6.

30.

Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.

Peeters SA, Engelen L, Buijs J, Jorsal A, Parving HH, Tarnow L, Rossing P, Schalkwijk CG, Stehouwer CDA.

Cardiovasc Diabetol. 2017 Apr 26;16(1):55. doi: 10.1186/s12933-017-0539-1.

31.

Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes.

Østergaard JA, Thiel S, Hoffmann-Petersen IT, Hovind P, Parving HH, Tarnow L, Rossing P, Hansen TK.

Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2895. Epub 2017 Apr 11.

PMID:
28303635
32.

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.

Oellgaard J, Gæde P, Rossing P, Persson F, Parving HH, Pedersen O.

Kidney Int. 2017 Apr;91(4):982-988. doi: 10.1016/j.kint.2016.11.023. Epub 2017 Feb 7. Erratum in: Kidney Int. 2017 May;91(5):1257.

PMID:
28187983
33.

Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with Type 1 diabetes.

Kristensen PL, Tarnow L, Bay C, Nørgaard K, Jensen T, Parving HH, Perrild H, Beck-Nielsen H, Christiansen JS, Thorsteinsson B, Pedersen-Bjergaard U.

Diabet Med. 2017 May;34(5):625-631. doi: 10.1111/dme.13317. Epub 2017 Feb 14.

PMID:
28099755
34.

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.

Pena MJ, de Zeeuw D, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Kohan DE, Makino H, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, Sharma S, Corringham T, Sharma K, Heerspink HJL.

Diabetes Obes Metab. 2017 May;19(5):749-753. doi: 10.1111/dom.12864. Epub 2017 Feb 22.

PMID:
28019071
35.

The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial.

Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, Jensen T, Parving HH, Thorsteinsson B, Tarnow L.

Diabetes Res Clin Pract. 2017 Jan;123:143-148. doi: 10.1016/j.diabres.2016.11.003. Epub 2016 Nov 16.

PMID:
28012403
36.

Comparison of exposure response relationship of atrasentan between North American and Asian populations.

Heerspink HJ, Makino H, Andress D, Brennan JJ, Correa-Rotter R, Coll B, Davis JW, Idler K, Kohan DE, Liu M, Perkovic V, Remuzzi G, Tobe SW, Toto R, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2017 Apr;19(4):545-552. doi: 10.1111/dom.12851. Epub 2017 Jan 27.

PMID:
27981738
37.

Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease.

Kröpelin TF, de Zeeuw D, Remuzzi G, Bilous R, Parving HH, Heerspink HJ.

J Am Soc Nephrol. 2016 Nov;27(11):3405-3412. Epub 2016 Apr 7.

38.

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.

Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, Pedersen O.

Diabetologia. 2016 Nov;59(11):2298-2307. doi: 10.1007/s00125-016-4065-6. Epub 2016 Aug 16.

39.

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.

Lindhardt M, Persson F, Zürbig P, Stalmach A, Mischak H, de Zeeuw D, Lambers Heerspink H, Klein R, Orchard T, Porta M, Fuller J, Bilous R, Chaturvedi N, Parving HH, Rossing P.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1866-1873. doi: 10.1093/ndt/gfw292.

PMID:
27507891
40.

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.

Persson F, Lindhardt M, Rossing P, Parving HH.

J Renin Angiotensin Aldosterone Syst. 2016 Aug 3;17(3). pii: 1470320316652047. doi: 10.1177/1470320316652047. Print 2016 Jul. Review.

41.

Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.

Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving HH.

J Diabetes Complications. 2016 Nov - Dec;30(8):1440-1442. doi: 10.1016/j.jdiacomp.2016.07.003. Epub 2016 Jul 16.

PMID:
27475262
42.

High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes.

Zobel EH, von Scholten BJ, Lajer M, Jorsal A, Tarnow L, Rasmussen LM, Holstein P, Parving HH, Hansen TW, Rossing P.

J Diabetes Complications. 2016 Nov - Dec;30(8):1603-1608. doi: 10.1016/j.jdiacomp.2016.07.008. Epub 2016 Jul 17.

PMID:
27469295
43.

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.

Pena MJ, Heinzel A, Rossing P, Parving HH, Dallmann G, Rossing K, Andersen S, Mayer B, Heerspink HJ.

J Transl Med. 2016 Jul 5;14(1):203. doi: 10.1186/s12967-016-0960-3.

44.

Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.

Agesen RM, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parving HH, Thorsteinsson B, Tarnow L, Pedersen-Bjergaard U.

Diabetes Metab. 2016 Sep;42(4):249-55. doi: 10.1016/j.diabet.2016.03.001. Epub 2016 Apr 7.

PMID:
27068361
45.

Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.

von Scholten BJ, Reinhard H, Hansen TW, Oellgaard J, Parving HH, Jacobsen PK, Rossing P.

Diabetologia. 2016 Jul;59(7):1549-1557. doi: 10.1007/s00125-016-3937-0. Epub 2016 Mar 31.

PMID:
27033561
46.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14.

PMID:
26774608
47.

Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.

von Scholten BJ, Reinhard H, Hansen TW, Schalkwijk CG, Stehouwer C, Parving HH, Jacobsen PK, Rossing P.

J Diabetes Complications. 2016 Mar;30(2):248-55. doi: 10.1016/j.jdiacomp.2015.11.005. Epub 2015 Nov 6.

PMID:
26651261
48.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2016 Feb;18(2):169-77. doi: 10.1111/dom.12600. Epub 2016 Jan 13.

PMID:
26511599
49.

Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes.

Schievink B, Kröpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink HJ.

Diabetes Obes Metab. 2016 Jan;18(1):64-71. doi: 10.1111/dom.12583. Epub 2015 Nov 27.

PMID:
26434564
50.

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.

Schievink B, de Zeeuw D, Smink PA, Andress D, Brennan JJ, Coll B, Correa-Rotter R, Hou FF, Kohan D, Kitzman DW, Makino H, Parving HH, Perkovic V, Remuzzi G, Tobe S, Toto R, Hoekman J, Lambers Heerspink HJ.

Eur J Prev Cardiol. 2016 May;23(7):758-68. doi: 10.1177/2047487315598709. Epub 2015 Jul 30.

PMID:
26229089

Supplemental Content

Loading ...
Support Center